Pd41-12 perioperative complications and outcomes of patients undergoing aquablation for benign prostatic hyperplasia: a single tertiary referral center experience in 146 patients

You have accessJournal of UrologyCME1 Apr 2023PD41-12 PERIOPERATIVE COMPLICATIONS AND OUTCOMES OF PATIENTS UNDERGOING AQUABLATION FOR BENIGN PROSTATIC HYPERPLASIA: A SINGLE TERTIARY REFERRAL CENTER EXPERIENCE IN 146 PATIENTS Alireza Ghoreifi, David Ortega Herrera, Michael Eppler, Randall Lee, Maria Lizana, Abhisek Venkat, Marissa Maas, Andre Abreu, Rene Sotelo, Mike Nguyen, Inderbir Gill, Leo Doumanian, Giovanni E. Cacciamani, and Mihir Desai Alireza GhoreifiAlireza Ghoreifi More articles by this author , David Ortega HerreraDavid Ortega Herrera More articles by this author , Michael EpplerMichael Eppler More articles by this author , Randall LeeRandall Lee More articles by this author , Maria LizanaMaria Lizana More articles by this author , Abhisek VenkatAbhisek Venkat More articles by this author , Marissa MaasMarissa Maas More articles by this author , Andre AbreuAndre Abreu More articles by this author , Rene SoteloRene Sotelo More articles by this author , Mike NguyenMike Nguyen More articles by this author , Inderbir GillInderbir Gill More articles by this author , Leo DoumanianLeo Doumanian More articles by this author , Giovanni E. CacciamaniGiovanni E. Cacciamani More articles by this author , and Mihir DesaiMihir Desai More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003346.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Most published data with Aquablation, a recently introduced minimally-invasive technology for management of patients with benign prostatic hyperplasia (BPH), is from 2 large multicenter trials. The aim of this study is to report post-commercialization perioperative complications and outcomes of Aquablation from a single institution. METHODS: Using our IRB-approved database, we retrospectively reviewed the records of consecutive patients who underwent Aquablation for BPH in our institution between August 2020 and June 2022. Those with no available 90-day data were excluded. Primary and secondary outcomes were 90-day complications (graded by Clavien-Dindo classification) and 90-day readmission, respectively. Specific focus was placed on hemorrhagic complications. Univariate and multivariable logistic regression were performed to assess the factors affecting the 90-day complications. RESULTS: Among 146 patients who received Aquablation during the study timeframe, 133 patients with a median (IQR) age of 69 (64 – 73) years and median (IQR) prostate size of 85 (65 – 109) mL were included in the analysis. Baseline and clinical features of the patients are presented in Table 1. Median operative time was 64 minutes, and no intraoperative complication/blood transfusion was recorded. Median length of hospital stay and catheter time were 1 and 3 days, respectively. 90-day complications were recorded in 36 patients (27%) with a Clavien 3 in 11 patients (8%). A bleeding event was recorded in 5 patients (4%) of whom 4 required cystoscopic fulguration (Table 2). Average drop in postoperative hemoglobin was 1.5 gm/dL, yet no patient required peri-operative blood transfusions. The readmission rate was 4.5% (6/133). Two patients underwent re-treatment (transurethral resection of the prostate). On multivariable analysis, prostate size was not independently associated with 90-day complications (OR 1.02, 95% CI 0.99 – 1.03, p=0.07). CONCLUSIONS: Aquablation is safe with a 27% overall complication rate that is independent of patient or prostate factors. Bleeding rate with incorporation of selective cautery hemostasis has dropped compared to the Water and Water 2 trial data. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1063 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alireza Ghoreifi More articles by this author David Ortega Herrera More articles by this author Michael Eppler More articles by this author Randall Lee More articles by this author Maria Lizana More articles by this author Abhisek Venkat More articles by this author Marissa Maas More articles by this author Andre Abreu More articles by this author Rene Sotelo More articles by this author Mike Nguyen More articles by this author Inderbir Gill More articles by this author Leo Doumanian More articles by this author Giovanni E. Cacciamani More articles by this author Mihir Desai More articles by this author Expand All Advertisement PDF downloadLoading ...